China has extended approval for Sinovac’s vaccine to children as young as three. This is reported by the news agency AFP. This is the first time in the world that an active ingredient has been approved for use in children under the age of twelve. This is an emergency approval. Sinovac intends to report on the initial results of ongoing studies in children and adolescents in the renowned journal “The Lancet” in the near future.
Continue reading now
Get 30 days of free access to the Decision Brief to read these and more quality news every day.
Are you already a guest at the China.Table? Log in now